Finerenone for Patients With Primary Aldosteronism (FAIRY)

PHASE4RecruitingINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Primary Aldosteronism
Interventions
DRUG

Finerenone Oral Tablet

Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).

DRUG

Spironolactone Oral Tablet

Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).

Trial Locations (1)

400016

RECRUITING

the first affiliated hospital of Chongqing medical university, Chongqing

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Affiliated Hospital Of Southwest Medical University

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

Changzhi Medical College

OTHER

lead

Qifu Li

OTHER

NCT06457074 - Finerenone for Patients With Primary Aldosteronism (FAIRY) | Biotech Hunter | Biotech Hunter